2018 CA JumpStart Grant Opens this August
PharmaDirections is pleased to announce that the fourth annual CA JumpStart Grant will launch this August. The JumpStart Grant provides the winning company with a comprehensive development plan that includes a strategic plan to IND, Gant chart, and itemized budget that can be used to raise funds and provide efficient execution (a non-cash grant, approximate value $25,000). Applicant companies should be privately-held therapeutic (small or large molecule biologics), combination drug/device, and/or diagnostic companies, located in California, with 1-2 people, or 4-5 part-time scientists. Their technology must have high potential, and they must be members of CLSA and/or Biocom.
STATegics, Inc. – a Bay Area-based CLSA Fellow company focused on the discovery and development of breakthrough new treatments for life-threatening rare neurodegenerative diseases – won the 2017 JumpStart grant. STATegics has identified novel small molecules to address the underlying cause of Friedreich’s ataxia (FA) – a rare neuromuscular disease for which no treatment is available – by targeting the tissue-protective cytokine receptor. In addition to addressing critical drivers in FA, STATegics’ molecules have the potential to treat multiple neuromuscular and neurodegenerative diseases.
Upon winning the JumpStart grant last November, Jeff Spencer, CEO of STATegics, engaged in extensive discussions with Michelle Higgin and Tilmann Brotz at PharmaDirections, who have provided key guidance on rare disease-focused development and regulatory planning, an essential resource for moving forward with the FA program. According to Spencer, “the development framework produced with the JumpStart program will be invaluable when talking to investors and potential partners about STATegics’ financing plans.”
“We truly enjoy helping the small drug development startups,” stated Cathi Rogers, VP of Business Development at PharmaDirections. “We’re hoping they’ll be successful and get where they want to be as a result of our collaboration and mentorship. We work with these companies as if they are our own clients because new small startups do not have the financial ability to establish their own development team.”
Application period for the 2018 CA JumpStart grant will be from August to November, and the winning company will be announced at the FAST Closing Showcase in December. For more information on the 2018 CA JumpStart grant, please visit http://PharmaDirections.com or contact Cathi Rogers at CRogers@pharmadirections.com.